Table 3.
Observed hepatitis C virus (HCV) antibody prevalence rates for male 16–49 year olds in five year age bands undergoing, or eligible to undergo, surgery
| Cardiothoracic/ cardiology | Orthopaedics/ rheumatology | General surgery/ENT | Total (prevalence %) | |
| 16–19 years | ||||
| Tested | 11 | 37 | 67 | 115 |
| Positive | 0 | 0 | 1 | 1 (0.9%) |
| 20–24 years | ||||
| Tested | 30 | 55 | 74 | 159 |
| Positive | 0 | 1 | 3 | 4 (2.5%) |
| 25–29 years | ||||
| Tested | 57 | 120 | 92 | 269 |
| Positive | 3 | 7 | 9 | 19 (7.1%) |
| 30–34 years | ||||
| Tested | 81 | 150 | 135 | 366 |
| Positive | 7 | 15 | 22 | 44 (12.0%) |
| 35–39 years | ||||
| Tested | 160 | 175 | 145 | 480 |
| Positive | 5 | 2 | 5 | 12 (2.5%) |
| 40–44 years | ||||
| Tested | 248 | 226 | 166 | 640 |
| Positive | 3 | 10 | 5 | 18 (2.8%) |
| 45–49 years | ||||
| Tested | 298 | 204 | 174 | 676 |
| Positive | 1 | 2 | 2 | 5 (0.7%) |